Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Duragesic
2. Durogesic
3. Fentanest
4. Fentanyl
5. Fentora
6. Phentanyl
7. R 4263
8. R-4263
9. R4263
10. Sublimaze
11. Transmucosal Oral Fentanyl Citrate
1. 990-73-8
2. Leptanal
3. Phentanyl Citrate
4. Actiq
5. Fentanyl Dihydrogen Citrate
6. Abstral
7. Fentanyl Citrate Salt
8. Lazanda
9. Onsolis
10. Mcn-jr-4263-49
11. Instanyl
12. Fentanyl Buccal
13. Fentanyl Citrate Cii
14. Mun5lyg46h
15. Oralet
16. N-(1-phenethyl-4-piperidyl)propionanilide Citrate
17. N-(1-phenethyl-4-piperidyl)propionanilide Citrate (1:1)
18. N-(1-phenethyl-4-piperidyl)propionanilide Dihydrogen Citrate
19. Chebi:31602
20. Fentaz
21. N-(1-phenethyl-4-piperidinyl)propionanilide Dihydrogen Citrate
22. R-4263
23. Kw-2246
24. Propanamide, N-phenyl-n-(1-(2-phenylethyl)-4-piperidinyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
25. N-(1-phenethylpiperidin-4-yl)-n-phenylpropionamide Citrate
26. Rapinyl
27. 2-hydroxypropane-1,2,3-tricarboxylic Acid;n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide
28. Mcn-jr 4263
29. Sublimaze Preservative Free
30. Einecs 213-588-0
31. Unii-mun5lyg46h
32. Fentanyl Citrate Preservative Free
33. R 5240
34. Fentanyl Monocitrate
35. Abstral (tn)
36. Fentora (tn)
37. Lazanda (tn)
38. Oralet (tn)
39. Fentanyl Citrate [usan:usp:ban:jan]
40. Propionanilide, N-(1-phenethyl-4-piperidyl)-, Citrate (1:1)
41. Chembl688
42. Schembl40733
43. Fentanyl Citrate [mi]
44. Fentanyl Citrate [jan]
45. Fentanyl Citrate (jp17/usp)
46. Fentanyl Citrate [usan]
47. Fentanyl Citrate [vandf]
48. Dtxsid80243933
49. Fentanyl Citrate [mart.]
50. Fentanyl Citrate [who-dd]
51. Fentanyl Citrate [ema Epar]
52. Fentanyl Citrate [green Book]
53. Akos024457504
54. Fentanyl Citrate [orange Book]
55. Fentanyl Citrate Cii [usp-rs]
56. Fentanyl Citrate [ep Monograph]
57. Fentanyl Citrate [usp Monograph]
58. Innovar Component Fentanyl Citrate
59. B5403
60. Fentanyl Citrate Component Of Innovar
61. D01399
62. 990f738
63. Q27104201
64. N-phenyl-n-[1-(2-phenylethyl)-4-piperidyl]propanamide Citrate
65. Fentanyl Citrate, European Pharmacopoeia (ep) Reference Standard
66. N-phenyl-n-[1-(2-phenylethyl)-4-piperidinyl]propanamide Citrate
67. Fentanyl Citrate, United States Pharmacopeia (usp) Reference Standard
68. Fentanyl Citrate Salt Solution, Drug Standard, 100 Mug/ml In Methanol: Tert-butanol (3:2)
69. N-(1-phenethylpiperidin-4-yl)-n-phenylpropionamide 2-hydroxypropane-1,2,3-tricarboxylate
70. N-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide 2-hydroxypropane-1,2,3-tricarboxylate
Molecular Weight | 528.6 g/mol |
---|---|
Molecular Formula | C28H36N2O8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 11 |
Exact Mass | 528.24716611 g/mol |
Monoisotopic Mass | 528.24716611 g/mol |
Topological Polar Surface Area | 156 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 618 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Abstral |
PubMed Health | Fentanyl |
Drug Classes | Analgesic, Anesthetic Adjunct |
Drug Label | ABSTRAL (fentanyl) sublingual tablet is a solid formulation of fentanyl citrate, a potent opioid analgesic intended for oral sublingual administration. ABSTRAL is formulated as a white tablet available in six strengths, distinguishable by the shape o... |
Active Ingredient | Fentanyl citrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 0.1mg base; eq 0.8mg base; eq 0.3mg base; eq 0.6mg base; eq 0.4mg base; eq 0.2mg base |
Market Status | Prescription |
Company | Galena Biopharma |
2 of 8 | |
---|---|
Drug Name | Fentanyl citrate |
Drug Label | Oral transmucosal fentanyl citrate is a solid formulation of fentanyl citrate, a potent opioid analgesic, intended for oral transmucosal administration. Oral transmucosal fentanyl citrate is formulated as a white to off-white solid drug matrix on a h... |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable; Troche/lozenge |
Route | Transmucosal; Injection |
Strength | eq 0.05mg base/ml; eq 0.8mg base; eq 1.6mg base; eq 0.6mg base; eq 1.2mg base; eq 0.4mg base; eq 0.2mg base |
Market Status | Prescription |
Company | Hospira; Mallinckrodt; Par Pharm |
3 of 8 | |
---|---|
Drug Name | Fentanyl citrate preservative free |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.05mg base/ml |
Market Status | Prescription |
Company | Hospira; Hikma Maple |
4 of 8 | |
---|---|
Drug Name | Sublimaze preservative free |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.05mg base/ml |
Market Status | Prescription |
Company | Akorn |
5 of 8 | |
---|---|
Drug Name | Abstral |
PubMed Health | Fentanyl |
Drug Classes | Analgesic, Anesthetic Adjunct |
Drug Label | ABSTRAL (fentanyl) sublingual tablet is a solid formulation of fentanyl citrate, a potent opioid analgesic intended for oral sublingual administration. ABSTRAL is formulated as a white tablet available in six strengths, distinguishable by the shape o... |
Active Ingredient | Fentanyl citrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 0.1mg base; eq 0.8mg base; eq 0.3mg base; eq 0.6mg base; eq 0.4mg base; eq 0.2mg base |
Market Status | Prescription |
Company | Galena Biopharma |
6 of 8 | |
---|---|
Drug Name | Fentanyl citrate |
Drug Label | Oral transmucosal fentanyl citrate is a solid formulation of fentanyl citrate, a potent opioid analgesic, intended for oral transmucosal administration. Oral transmucosal fentanyl citrate is formulated as a white to off-white solid drug matrix on a h... |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable; Troche/lozenge |
Route | Transmucosal; Injection |
Strength | eq 0.05mg base/ml; eq 0.8mg base; eq 1.6mg base; eq 0.6mg base; eq 1.2mg base; eq 0.4mg base; eq 0.2mg base |
Market Status | Prescription |
Company | Hospira; Mallinckrodt; Par Pharm |
7 of 8 | |
---|---|
Drug Name | Fentanyl citrate preservative free |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.05mg base/ml |
Market Status | Prescription |
Company | Hospira; Hikma Maple |
8 of 8 | |
---|---|
Drug Name | Sublimaze preservative free |
Active Ingredient | Fentanyl citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.05mg base/ml |
Market Status | Prescription |
Company | Akorn |
Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
Treatment of acute pain, Prevention of acute pain
Acute pain
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
Anesthetics, Intravenous
Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)
Narcotics
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
N02AB03
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
54
PharmaCompass offers a list of Fentanyl Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fentanyl Citrate manufacturer or Fentanyl Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fentanyl Citrate manufacturer or Fentanyl Citrate supplier.
PharmaCompass also assists you with knowing the Fentanyl Citrate API Price utilized in the formulation of products. Fentanyl Citrate API Price is not always fixed or binding as the Fentanyl Citrate Price is obtained through a variety of data sources. The Fentanyl Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LAZANDA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LAZANDA, including repackagers and relabelers. The FDA regulates LAZANDA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LAZANDA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LAZANDA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LAZANDA supplier is an individual or a company that provides LAZANDA active pharmaceutical ingredient (API) or LAZANDA finished formulations upon request. The LAZANDA suppliers may include LAZANDA API manufacturers, exporters, distributors and traders.
click here to find a list of LAZANDA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LAZANDA DMF (Drug Master File) is a document detailing the whole manufacturing process of LAZANDA active pharmaceutical ingredient (API) in detail. Different forms of LAZANDA DMFs exist exist since differing nations have different regulations, such as LAZANDA USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LAZANDA DMF submitted to regulatory agencies in the US is known as a USDMF. LAZANDA USDMF includes data on LAZANDA's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LAZANDA USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LAZANDA suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The LAZANDA Drug Master File in Japan (LAZANDA JDMF) empowers LAZANDA API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the LAZANDA JDMF during the approval evaluation for pharmaceutical products. At the time of LAZANDA JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of LAZANDA suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LAZANDA Drug Master File in Korea (LAZANDA KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LAZANDA. The MFDS reviews the LAZANDA KDMF as part of the drug registration process and uses the information provided in the LAZANDA KDMF to evaluate the safety and efficacy of the drug.
After submitting a LAZANDA KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LAZANDA API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LAZANDA suppliers with KDMF on PharmaCompass.
A LAZANDA CEP of the European Pharmacopoeia monograph is often referred to as a LAZANDA Certificate of Suitability (COS). The purpose of a LAZANDA CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of LAZANDA EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of LAZANDA to their clients by showing that a LAZANDA CEP has been issued for it. The manufacturer submits a LAZANDA CEP (COS) as part of the market authorization procedure, and it takes on the role of a LAZANDA CEP holder for the record. Additionally, the data presented in the LAZANDA CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the LAZANDA DMF.
A LAZANDA CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. LAZANDA CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of LAZANDA suppliers with CEP (COS) on PharmaCompass.
A LAZANDA written confirmation (LAZANDA WC) is an official document issued by a regulatory agency to a LAZANDA manufacturer, verifying that the manufacturing facility of a LAZANDA active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LAZANDA APIs or LAZANDA finished pharmaceutical products to another nation, regulatory agencies frequently require a LAZANDA WC (written confirmation) as part of the regulatory process.
click here to find a list of LAZANDA suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LAZANDA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LAZANDA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LAZANDA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LAZANDA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LAZANDA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LAZANDA suppliers with NDC on PharmaCompass.
LAZANDA Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LAZANDA GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LAZANDA GMP manufacturer or LAZANDA GMP API supplier for your needs.
A LAZANDA CoA (Certificate of Analysis) is a formal document that attests to LAZANDA's compliance with LAZANDA specifications and serves as a tool for batch-level quality control.
LAZANDA CoA mostly includes findings from lab analyses of a specific batch. For each LAZANDA CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LAZANDA may be tested according to a variety of international standards, such as European Pharmacopoeia (LAZANDA EP), LAZANDA JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LAZANDA USP).